In a US study, patients with severe eosinophilic esophagitis (EoE) by Index of Severity for EoE had poor responses to topical corticosteroid therapy.

NS-229 is an investigational selective Janus kinase 1 inhibitor designed to prevent tissue damage caused by EGPA by suppressing immune cell activation.